Fate Therapeutics to Present at Upcoming June Investor Conferences
May 31, 2023 08:00 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...
Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates
May 03, 2023 16:01 ET
|
Fate Therapeutics, Inc.
Dose Escalation Ongoing in Landmark Phase 1 Study of FT819 CD19-targeted 1XX CAR T-cell Program; Interim Clinical Data Demonstrated Favorable Safety Profile and Complete Responses in Aggressive Large...
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2023 Financial Results
April 24, 2023 08:00 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, April 24, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...
DEADLINE ALERT for YMAB, and FATE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
March 20, 2023 12:05 ET
|
The Law Offices of Frank R. Cruz
LOS ANGELES, March 20, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
DEADLINE ALERT for GWH, BVS, YMAB, and FATE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
March 13, 2023 12:24 ET
|
The Law Offices of Frank R. Cruz
LOS ANGELES, March 13, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
DEADLINE ALERT for GWH, BVS, YMAB, and FATE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
March 06, 2023 11:50 ET
|
The Law Offices of Frank R. Cruz
LOS ANGELES, March 06, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
Fate Therapeutics to Present at Upcoming March Investor Conferences
March 03, 2023 16:01 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, March 03, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FATE
March 01, 2023 11:34 ET
|
The Rosen Law Firm PA
NEW YORK, March 02, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ: FATE) between April 2,...
Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
February 28, 2023 16:01 ET
|
Fate Therapeutics, Inc.
Ended 2022 with Approximately $475 Million in Cash, Cash Equivalents, and Receivables Multi-dose Treatment Cohorts Initiated in FT576 Phase 1 Study for Multiple Myeloma; Interim Clinical Data from...
DEADLINE ALERT for GWH, BVS, YMAB, and FATE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
February 28, 2023 12:15 ET
|
The Law Offices of Frank R. Cruz
LOS ANGELES, Feb. 28, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...